Literature DB >> 15557143

Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells.

Michelle M Sandau1, Kimberly S Schluns, Leo Lefrancois, Stephen C Jameson.   

Abstract

IL-15 is critical for generation of multiple lymphoid subsets. Recent data have demonstrated a unique aspect of responses to IL-15, in that cells bearing the IL-15Ralpha chain can bind soluble IL-15 and "transpresent" the cytokine to other cells, allowing the latter to respond to IL-15. However, it is unclear whether IL-15 is normally secreted and then becomes bound to surface IL-15Ralpha on bystander cells, or whether transpresentation is mediated by the same cells which synthesize IL-15. Using mixed bone marrow chimeric mice, we present evidence for the latter model, showing that development of NK cells and memory phenotype CD8 T cells necessitates that both IL-15 and IL-15Ralpha be expressed by the same population of cells. These data argue that soluble forms of IL-15 are irrelevant for physiological responses to this cytokine, and the implications of this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557143     DOI: 10.4049/jimmunol.173.11.6537

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

Review 1.  Once a killer, always a killer: from cytotoxic T cell to memory cell.

Authors:  Leo Lefrançois; Joshua J Obar
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

Authors:  Bradley W Blaser; Noah R Schwind; Seth Karol; Dennis Chang; Samuel Shin; Sameek Roychowdhury; Brian Becknell; Amy K Ferketich; Donna F Kusewitt; Bruce R Blazar; Michael A Caligiuri
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

4.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

5.  Selective dependence of H2-M3-restricted CD8 responses on IL-15.

Authors:  Jürgen R Müller; Thomas A Waldmann; Sigrid Dubois
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

6.  The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.

Authors:  Noriko Sato; Hiral J Patel; Thomas A Waldmann; Yutaka Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

7.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

8.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27

9.  Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation.

Authors:  Spencer W Stonier; Lisa J Ma; Eliseo F Castillo; Kimberly S Schluns
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

10.  The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.